Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Breakthrough Therapy Designation To Idorsia's Daridorexant For Pediatric Insomnia

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

The FDA has granted Breakthrough Therapy Designation to Idorsia's drug Daridorexant for treating pediatric insomnia, accelerating its development and review process.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your biotech startup tackling paediatric sleep disorders can now pitch faster FDA approval paths as this shows regulator appetite for innovation in this area. Accelerating drug approval timelines can either open a white space or intensify competition rapidly.

◆ Coverage

2 sources · 4 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdabreakthrough-therapypediatric-insomniadrug-development